In addition, high expression levels of STAP1 were not associated with a poor five-year EFS, high MRD levels, or ex vivo resistance to chemotherapeutic drugs that are traditionally used in the treatment of BCP-ALL. Here, STAP1 is linked to acute lymphoblastic leukemia.